HOSPITALIZATION COSTS AND THEIR PREDICTORS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN URBAN CHINA
Author(s)
Yang L1, Zhang Y1, Wu J1, Dong P2, Xie X3, Tang B41Peking University, Beijing, Beijing, China, 2Pfizer China, Beijing, Beijing, China, 3Medical Science Development & Cooperation, Pfizer China, Beijing, China, 4Pfizer, New York, NY, USA
OBJECTIVES: Rheumatoid arthritis (RA) is associated with poor quality of life and higher healthcare cost. This study aimed to assess the hospitalization costs of rheumatoid arthritis (RA) and to characterize predictors of these costs. METHODS: A total of 676 RA patients were randomly selected by stratified two-stage sampling from the China Basic Health Insurance database in 2009 and 2008. All information of patient demographic characters, clinical and costs were collected for the analysis. We used generalized estimating equations to examine potential predictors of the costs. RESULTS: Among 676 RA patients (mean age = 57.8 years;75.2% female), The mean hospital length-of-stay was 19.4 days for RA patients with basic medical insurance for urban employees and 15.0 days for those patients with basic medical insurance for urban residents. The average inpatient cost was Chinese Yuan (CNY) 8521.5 (median:6608.7, IQR:4223.5-10383.3), higher than those without RA(CNY 7670) and the average drug cost accounts for 49.95% of the total cost (mean: 4256.9; median:3681.7, IQR:1973.7-5295.3). The multiple linear regressions showed that the hospital cost of patients with basic medical insurance for urban employees had 39.6% higher costs than those with basic medical insurance for urban residents(P<0.001). Patients from tertiary hospitals had 97.8% higher costs than those from primary hospitals; (P <0.001) and patients from municipalities had 46.0% higher costs than those from county-level cities( P <0.01). CONCLUSIONS: Patients with RA is associated with high hospitalization costs. Costs are now driven predominantly by the cost of drugs, primarily biologic agents. and sociodemographic characteristics such as types of health insurance and levels of hospitals also play an important role in determination of costs.
Conference/Value in Health Info
2012-09, ISPOR Asia Pacific 2012, Taipei, Taiwan
Value in Health, Vol. 15, No. 7 (November 2012)
Code
PMS10
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Musculoskeletal Disorders